Constipation Predominant Irritable Bowel Syndrome (c-IBS)
A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled,
Parallel Group Study of Renzapride
in Women
with
Constipation-Predominant Irritable Bowel Syndrome (c-IBS)
In this study, female patients with constipation predominant IBS will receive one of two dosing regimens (Renzapride or placebo) for 12 weeks. Patients will record the severity of their symptoms throughout the study. The results will be analyzed to see if those patients who received Renzapride had greater relief of their symptoms than did the patients who received placebo.
Eligibility
Ages for Study: |
18 - 65 Years |
Gender for study: |
Female |
| Some of the criteria for qualifying for the study are shown below. Please call the contact person (below) to find out if you qualify. |
Inclusion Criteria:
- Females with constipation predominant IBS as defined by the Rome II criteria
- Colonoscopy or sigmoidoscopy in previous 5 years showed no significant disease
Exclusion Criteria:
- Patients who have diarrhea predominant or alternating symptom IBS
- Other gastrointestinal diseases that affect bowel transit
|
Contact:
Gerry Powers, RN, CCRC, Study Coordinator
Pinehurst Medical Clinic
205 Page Rd.,
Pinehurst, NC 28374
Telephone: 910-255-4314 |
|
|
